NULOJIX REMS website

 

This communication is intended to inform AST about the important safety information for NULOJIX (r) (belatacept), a selective T-cell costimulation blocker recently approved by the Food and Drug Administration (FDA) for the prophylaxis of organ rejection in adult patients receiving a kidney transplant. NULOJIX is to be used in combination with basiliximab induction, mycophenolate mofetil (MMF), and corticosteroids. NULOJIX is indicated for use only in transplant patients who are Epstein-Barr virus (EBV) seropositive. Use of NULOJIX for the prophylaxis of organ rejection in other transplanted organs has not been established.

The FDA has determined that a Risk Evaluation and Mitigation Strategy (REMS) is necessary to ensure that the benefits of NULOJIX outweigh the risks of post-transplant lymphoproliferative disorder (PTLD) and progressive multifocal leukoencephalopathy (PML), both of which can be fatal.

The NULOJIX REMS is designed to inform healthcare providers about the increased risk of PTLD, predominantly involving the central nervous system (CNS), and PML with NULOJIX. In order for Bristol-Myers Squibb to communicate certain risks about NULOJIX, Bristol-Myers Squibb has worked with the FDA to develop materials for a more complete description of the risks including PTLD and PML.

The NULOJIX Full Prescribing Information and REMS materials, are available below.

Prescribing Information
Important Drug Warning
HCP Fact Sheet

For more information, please visit: http://www.nulojix.com/REMS.aspx

Educational Content Disclaimer: The content, information, opinions, and viewpoints contained in educational materials housed on and linked from the AST web site are those of the authors or contributors of such materials. While the AST and its committees take great care to screen the credentials of the contributors and make every attempt to review the contents, AST MAKES NO WARRANTY, EXPRESSED OR IMPLIED, as to the completeness or accuracy of the content contained in the educational materials or on this website. The reader of these materials uses these materials at his or her own risk, and AST shall not be responsible for any errors, omissions, or inaccuracies in these materials, whether arising through negligence, oversight, or otherwise. Reliance on any information appearing on this site is strictly at your own risk. Read the full disclaimer.